SCM
PLRX icon

Stonepine Capital Management’s Pliant Therapeutics PLRX Stock Holding History

Stonepine Capital Management’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$263K Buy
230,538
+5,888
+3% +$7.17K 0.15% 74
2026
Q1 		$283K Sell
224,650
-5,400
-2% -$6.82K 0.11% 66
2025
Q4 		$281K Sell
230,050
-59,187
-20% -$88.9K 0.2% 55
2025
Q3 		$428K Buy
+289,237
New +$441K 0.35% 44

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Stonepine Capital Management's PLRX Position: Q2 2026 in Review

Stonepine Capital Management increased its Pliant Therapeutics (PLRX) stake by 2.6% in Q2 2026, buying an estimated $7.17K and bringing the position to 230,538 shares worth $263K. The position accounts for 0.15% of the portfolio, ranked #74.

Stonepine Capital Management first reported a position in PLRX in Q3 2025 and has held it in 4 quarters since. The position peaked at $428K in Q3 2025. 86 funds tracked by Wall St. Rank hold PLRX as of Q2 2026.

  • Stonepine Capital Management held 230,538 shares of Pliant Therapeutics worth $263K as of Q2 2026.
  • Stonepine Capital Management bought 5,888 Pliant Therapeutics shares in Q2 2026, an estimated $7.17K.
  • Pliant Therapeutics made up 0.15% of Stonepine Capital Management's portfolio in Q2 2026, its #74 holding.
  • Stonepine Capital Management first reported a position in Pliant Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Stonepine Capital Management's Pliant Therapeutics position peaked at $428K in Q3 2025.
  • 86 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2026.

Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.